This Case Study demonstrates how the use of Akadeum’s microbubble platform offers a simple and highly tunable isolation and activation workflow that generates T cells ready for suspended cell culture and downstream applications, such as genetic modification and expansion, and discusses the potential impact of the solution on cancer treatment. 

The burden of cancers in both expense and loss of life is staggering. One in four deaths in the United States is due to cancer, and the estimated cost of cancer care in 2020 was over $200 billion [1]. In the US, 8 of the top 10 most prevalent cancer types, as measured by both new cases and cancer-related deaths, present as solid tumors [2]. Chimeric antigen receptor (CAR)-T cell therapy was developed to address this. These T cells have been genetically engineered to express a unique receptor that recognizes specific proteins on the surface of the patient’s cancer cells. These cells are expanded in the laboratory and injected into patients, where they find and eliminate cancer cells throughout the body, including within solid tumors. This therapy can be tailor-made to clear various cancer types while reducing the need for harmful treatments such as chemotherapy and radiation therapy. While hundreds of CAR-T cell therapy clinical trials are currently underway worldwide, there are still significant roadblocks to creating efficient, cost-effective, and scalable workflows.

For this Case Study, the Akadeum team demonstrates how the application of microbubbles in addressing these roadblocks, before explaining the impact of this solution on the burden that cancer places on society. Download the full Case Study to find out more. 

This Case Study has been produced in partnership with Akadeum Life Sciences.